AllSci News
Mirai Bio and A*STAR team up to improve lung delivery of nucleic acid therapies
Cambridge, Massachusetts-based Mirai Bio and Singapore's A\STAR Institute of Molecular and Cell Biology (A\STAR IMCB) announced a research collaboration...
Pretzel’s POLG activator gains FDA Fast Track ahead of Phase II POLG disease trial
Waltham, Massachusetts-based Pretzel Therapeutics announced receipt of US FDA Fast Track Designation for PX578, a central nervous system-penetrant small...
Scarlet Therapeutics leads USD 14m DARPA-backed UK smart red blood cell consortium
UK-based Scarlet Therapeutics Ltd has secured a research agreement with the Defense Advanced Research Projects Agency (DARPA) worth up to USD 14 million to...
Norway’s Oncoinvent raises USD 16.2m to fund radiopharmaceutical ovarian cancer trial
Norway-based Oncoinvent ASA has completed the bookbuilding and allocation for a private placement and retail offering expected to raise NOK 148.5 million...
Roche's sefaxersen meets Phase III primary endpoint in IgA nephropathy trial
Roche's sefaxersen, a liver-directed antisense oligonucleotide (ASO) targeting complement factor B, met its primary endpoint in a Phase III trial in IgA...
EU approves AstraZeneca's Trixeo as first triple-combination inhaler for inadequately controlled asthma
The European Commission has approved Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) as a maintenance treatment for asthma in...
Grünenthal expands into oncology with EUR 375 million Stivarga acquisition from Bayer
Privately held, Germany-based pharma company Grünenthal GmbH has agreed to acquire Stivarga (regorafenib), Bayer AG's (XETRA: BAYN) oral multikinase...
Siemens Healthineers, Novo partner to expand non-invasive liver fibrosis testing in MASH
Siemens Healthineers (XETRA: SHL) and Novo announced a collaboration to expand awareness and non-invasive blood-based testing for metabolic...
SystImmune hits USD 250m milestone from BMS as iza-bren Phase III lung cancer trial advances
Achievement of a milestone in the global Phase III registration trial IZABRIGHT-Lung02 has triggered a USD 250 million near-term milestone payment to...
Longeveron starts strategic review after laromestrocel failure to improve heart function in HLHS infants
Longeveron Inc.'s (Nasdaq: LGVN) laromestrocel failed to improve right ventricular function in infants with hypoplastic left heart syndrome (HLHS),...
Henlius looks to US biotech for global TCE rights in Amberstone deal
Shanghai Henlius Biotech, Inc. (HKEX: 2696) has licensed two oncology T cell engager (TCE) programs from Irvine, California-based Amberstone Biosciences,...
Zealand launches Phase III program for amylin analog petrelintide in overweight and obesity
Copenhagen-based Zealand Pharma A/S (Nasdaq: ZEAL) has initiated the registrational Phase III ZUPREME program for petrelintide, its long-acting amylin...
Otsuka's ulefnersen becomes first to hit primary endpoint in placebo-controlled FUS-ALS trial
Otsuka Pharmaceutical's ulefnersen met the primary endpoint of its Phase III FUSION trial in FUS-ALS, delivering the first statistically significant result...
Vertex posts Phase II data extending inaxaplin's reach in AMKD patient populations
Vertex Pharmaceuticals (Nasdaq: VRTX) reported positive Phase IIb data for inaxaplin in two APOL1-mediated kidney disease (AMKD) populations not enrolled in...
Quoin advances QRX003 in peeling skin syndrome with second FDA Fast Track
The FDA has granted Fast Track Designation to QRX003, Ashburn, Virginia-based Quoin Pharmaceuticals Ltd.'s (Nasdaq: QNRX) investigational topical serine...
The AllSci Brief
Free, systematic R&D and deal news. Daily.